The study, titled “Transcriptional profiling of antidepressant ketamine and electroconvulsive therapy treatment,” focuses on transcription—the process through which information encoded in DNA is copied into messenger RNA. Messenger RNA serves as an intermediate blueprint for protein production, and changes in its abundance can reveal which cellular programs have been activated or suppressed. Transcriptional profiling therefore offers a molecular snapshot of how tissue responds to treatment, potentially exposing patterns that are invisible when researchers measure symptoms alone.

Ketamine and ECT are separated by decades of medical history and by radically different modes of action. Ketamine is an anesthetic and a non-competitive antagonist of the N-methyl-D-aspartate, or NMDA, receptor, a protein involved in glutamate signaling. At carefully controlled doses, ketamine can produce rapid reductions in depressive symptoms, including in some patients who have not responded to standard antidepressants. Its effects are thought to involve a cascade of downstream events affecting synaptic plasticity, the capacity of neural connections to strengthen, weaken or reorganize.

ECT, by contrast, uses a controlled electrical stimulus to induce a brief therapeutic seizure under general anesthesia. Although its public image remains controversial, ECT is one of the most effective treatments available for severe depression, particularly when illness includes psychosis, intense suicidality or profound functional decline. The treatment triggers widespread changes in brain activity and is believed to influence neurotransmitter systems, neurotrophic signaling and the growth or remodeling of synaptic networks. Its biological complexity makes it especially valuable for studies seeking broad molecular signatures of recovery.

By comparing transcriptional profiles associated with ketamine and ECT, the researchers are exploring whether the two treatments activate overlapping gene-expression programs despite their different immediate targets. Such convergence could help explain why both therapies can improve mood and cognition on a compressed timescale. Alternatively, distinct transcriptional signatures might reveal that the treatments reach clinical improvement through separate biological routes. The answer could help researchers distinguish mechanisms directly linked to antidepressant action from changes that simply reflect anesthesia, seizure activity, stress responses or other treatment-related effects.

A key concept in this type of research is differential gene expression. Investigators compare the abundance of RNA transcripts between treated and untreated conditions, then use statistical models to identify genes whose activity changes beyond what would be expected from normal biological variation. The affected genes can be organized into pathways, such as synaptic signaling, immune regulation, energy metabolism, stress responses or neuroplasticity. These analyses do not prove that a particular gene causes recovery, but they can identify networks that deserve further testing in cellular, animal and clinical studies.

The molecular data may also contribute to the search for biomarkers. A biomarker is a measurable biological feature that could help predict who will respond to a treatment, how quickly improvement might occur or whether adverse effects are likely. Depression is not a single biological disorder; patients with similar symptoms may have different underlying mechanisms. If ketamine and ECT produce distinguishable transcriptional patterns, those signatures could eventually support more individualized treatment decisions. However, such applications would require replication in larger and more diverse patient populations, as well as validation in samples that can be collected routinely in clinical practice.

The study’s importance extends beyond a simple comparison between two therapies. Conventional antidepressants often require weeks before their full effects become apparent, and many patients experience incomplete relief. Rapid-acting treatments have therefore become a major focus of neuroscience. Understanding their molecular consequences could reveal new drug targets capable of reproducing beneficial plasticity without requiring anesthesia, repeated infusions or electrically induced seizures. It could also clarify whether rapid symptom improvement depends on repairing disrupted neural circuits, recalibrating stress-related systems or reshaping communication between brain cells.

At the same time, transcriptional profiles must be interpreted with care. Gene activity varies according to cell type, brain region, treatment timing, age, sex, previous medication exposure and the severity of illness. Measurements taken from blood, for example, may not perfectly represent changes occurring inside neural circuits. RNA changes can also be consequences rather than causes of clinical improvement. The value of the new work will therefore lie not only in the genes it highlights, but in how convincingly those findings connect molecular shifts with treatment response and, ultimately, patient outcomes.

By placing ketamine and ECT within a shared molecular framework, the research offers a route toward understanding why some interventions can rapidly alter the course of severe depression. The findings may help transform treatments that are currently selected largely through clinical experience into therapies guided by measurable biology. For now, the study represents an important step in mapping the transcriptional landscape of rapid antidepressant action—and in identifying the cellular programs that could power the next generation of depression treatments.

Subject of Research: Transcriptional and molecular effects of ketamine and electroconvulsive therapy as antidepressant treatments

Article Title: Transcriptional profiling of antidepressant ketamine and electroconvulsive therapy treatment

Article References: Zavaliangos-Petropulu, A., Ghang, G., Boltz, T. et al. “Transcriptional profiling of antidepressant ketamine and electroconvulsive therapy treatment.” Translational Psychiatry (2026). https://doi.org/10.1038/s41398-026-04196-y

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-026-04196-y

Keywords: ketamine, electroconvulsive therapy, depression, transcriptional profiling, gene expression, antidepressant treatment, neuroplasticity, molecular psychiatry

Anhedonia, the diminished ability to experience pleasure, is a core symptom of depression that often resists conventional treatments. Understanding its neural underpinnings and identifying predictors of therapeutic response have been significant challenges for clinicians and neuroscientists alike. Abram and colleagues addressed this by examining how motivational behaviors during specific reward-related tasks correlate with clinical improvements post-rTMS therapy.

The study employed a translational reward task designed to mimic real-world scenarios where patients actively pursue rewards, thereby engaging motivational circuitry in the brain. By quantifying reward-seeking behavior before treatment, the team could assess the extent to which these behavioral markers predicted reductions in anhedonia following rTMS. Their results demonstrated a robust positive correlation: patients who exhibited greater engagement in reward pursuit tasks showed more pronounced amelioration of anhedonic symptoms after receiving rTMS.

rTMS, a non-invasive brain stimulation technique, modulates neuronal activity in targeted brain regions implicated in mood regulation. Despite its FDA approval for treatment-resistant depression, patient responses vary widely. The findings from this study suggest that behavioral assays capturing motivational drive could serve as predictive biomarkers, enabling personalized optimization of rTMS protocols for individuals with MDD.

On a mechanistic level, the research highlights the importance of mesolimbic pathways, particularly dopamine-mediated circuits, in mediating both motivational behavior and therapeutic outcomes. Engagement in reward pursuit appears to reflect the functional integrity of these circuits, which rTMS may help restore or enhance. This aligns with growing evidence that depression’s neurobiology extends beyond serotonin deficits to include complex dysfunctions in reward processing networks.

Clinically, integrating behavioral measures with neuromodulation strategies could revolutionize treatment planning. The ability to identify patients most likely to benefit from rTMS before initiating therapy promises greater efficiency and reduced trial-and-error approaches. Furthermore, adapting rTMS parameters based on reward task performance might further amplify symptomatic relief, ushering in a new era of precision psychiatry.

This research also opens avenues for future exploration into other neuropsychiatric conditions characterized by reward-processing deficits. The translational reward task paradigm and the emphasis on motivational engagement could inform interventions for disorders such as schizophrenia, addiction, and bipolar disorder, where anhedonia and reward dysfunction are prevalent.

While these findings are promising, the authors note the necessity for larger longitudinal studies to validate and refine these predictive behavioral markers. Additionally, combining neuroimaging data with behavioral assessments could elucidate the neural substrates underlying individual differences in treatment response.

In summary, the study by Abram et al. represents a significant advance in understanding how reward-related behaviors can forecast therapeutic outcomes in depression. By leveraging translational neuroscience and innovative therapeutic techniques like rTMS, this research paves the way for more effective, individualized interventions aimed at conquering one of psychiatry’s most debilitating symptoms.

Subject of Research: Reward pursuit behavior and its correlation with anhedonia reduction following rTMS treatment in major depressive disorder patients

Article Title: Reward pursuit during a translational reward task correlates with anhedonia reductions following rTMS in patients with major depressive disorder

Article References: Abram, S.V., McInnes, A.N., Sullivan, C.R.P. et al. Reward pursuit during a translational reward task correlates with anhedonia reductions following rTMS in patients with major depressive disorder. Transl Psychiatry (2026). https://doi.org/10.1038/s41398-026-04248-3

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-026-04248-3